<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02413918</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20120137</org_study_id>
    <nct_id>NCT02413918</nct_id>
  </id_info>
  <brief_title>Iloperidone in Mixed States of Bipolar Disorder</brief_title>
  <official_title>Open Label Study of Iloperidone (IL) as Adjunctive Treatment in Mixed States (MS) of Bipolar Disorder (BD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanda Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. To assess the acute and long-term bimodal efficacy of iloperidone (IL), as an adjunct to
           ongoing treatment with lithium (Li) or divalproex (DIV) or lamotrigine (LAM) or any
           combination of the three thereof, in a group of patients with an index episode of a
           mixed state in BD.

        2. To assess background, baseline features, and behavioral components which characterize
           treatment response/non-response in the acute and long term management of MS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective 20-week, open-label study of iloperidone added to ongoing treatment
      regimen with mood stabilizers (Li or DIV or LAM or any combination of these) in the acute and
      maintenance treatment of MS- Total number of subjects: 40.

      Severity of the illness and psychopathological features will be measured by the following
      rating scales: YMRS, MADRS, CGI-S and GAS, and the BISS .

      The study will monitor the safety and tolerability of the combination iloperidone plus mood
      stabilizers.

      Efficacy Measures: Primary efficacy measures include 1) Mixed effects repeat measure of
      change from baseline in BISS total score and, secondarily, manic and depression subscale
      scores.

      Secondary Efficacy Measures: 1) response defined as 50% reduction in YMRS and MADRS and 2)
      Time to intervention or discontinuation for any mood episode.

      Iloperidone will be initiated at 2 mg at hs on day 1 with increase to 4mg at hs on day 2, 8
      mg at hs on day 3. All patients will have iloperidone titrated to receive a dosage of at
      least 12 mg a day. Dosages can be titrated up to 24 mg a day based on tolerability and
      clinical indication. Dosage of iloperidone can be reduced to 6 mg a day if patients develop
      side effects necessitating a reduction in the dosage
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores</measure>
    <time_frame>Baseline and 20 weeks</time_frame>
    <description>The Bipolar Inventory of Symptoms Scale is a reliable and valid measure which assesses Depression and Mania symptoms of bipolar disorder. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period.
For Depression: Items 1-21 items of the assessment are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the depression.
For Mania: Items 22-42 are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the mania. The mean is calculated from the change in score between baseline and week 20.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Open Label iloperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iloperidone</intervention_name>
    <description>Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.</description>
    <arm_group_label>Open Label iloperidone</arm_group_label>
    <other_name>Fanapt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female;

          2. Age 18 years and older

          3. Patients on:

               -  Li at a stable dose for 2 weeks or longer, and a serum level at screening of
                  greater than or equal to 0.5 mEq/l OR

               -  DIV dose for 2 weeks or longer, and a serum level at screening of greater than or
                  equal to 45 ug/ml OR

               -  LAM (dosage/day â‰¥100mg) at a stable dose for 2 weeks or longer OR

               -  Any combination 3a, 3b, or 3c

          4. Patients meeting DSM-IV TR diagnosis of bipolar disorder, I or II, as assessed using
             the MINI, (Sheehan et al., 1998) PLUS any ONE of criteria 5 or 6 or 7

          5. Patients meeting DSM-IV TR diagnostic criteria for a mixed manic episode with Young
             Mania Rating Scale (YMRS) score&gt;/=14 and Montgomery Asberg Depression Rating Scale
             (MADRS) score&gt;/=14

          6. Patients meeting the criteria for a manic/hypomanic episode for at least 2 days with
             the simultaneous presence of Young Mania Rating Scale (YMRS) score&gt;/=14 PLUS
             Montgomery Asberg Depression Rating Scale (MADRS) score&gt;/=14 ;

          7. Patients meeting DSM-IV TR diagnostic criteria for a major depressive episode with the
             simultaneous presence of MADRS score&gt;/=14 PLUS meeting the criteria for a
             manic/hypomanic episode for at least 2 days with the simultaneous presence of Young
             Mania Rating Scale (YMRS) score&gt;/=14

        Exclusion Criteria:

          1. Patients with a current Axis I diagnosis of schizophrenia, schizophreniform disorder,
             schizotypal disorder, bipolar disorder with psychotic sub-type that requires
             hospitalization, drug induced mania or AIDS induced mania

          2. Women with a positive pregnancy test or who are lactating

          3. Women of child-bearing potential who are not practicing a clinically accepted method
             of contraception

          4. Patients with general medical conditions that contraindicate psychoactive medications
             or uncontrolled medical disorder or central nervous system diseases.

          5. Patients whose clinical status requires inpatient or day hospital treatment

          6. History of severe side effects associated with therapeutic doses of Li, DIV, LAM

          7. Alcohol or drug dependent at time of enrollment

          8. Suicidal at time of enrollment.

          9. Current or previous exposure to iloperidone

         10. Patients taking medication that cause QTC prolongation

         11. Patients with serious cardiac disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Health Science Center San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT Health Science Center San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2015</study_first_submitted>
  <study_first_submitted_qc>April 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2015</study_first_posted>
  <results_first_submitted>April 21, 2015</results_first_submitted>
  <results_first_submitted_qc>October 5, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">November 6, 2017</results_first_posted>
  <last_update_submitted>January 12, 2018</last_update_submitted>
  <last_update_submitted_qc>January 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mixed episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred April 2013 to April 2015 from patients in the clinic or from responders to t.v. advertisements.</recruitment_details>
      <pre_assignment_details>Subjects who met inclusion criteria at screening visit were started on study medication at visit 2.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Open Label Iloperidone</title>
          <description>open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
iloperidone: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subject meeting inclusion criteria</population>
      <group_list>
        <group group_id="B1">
          <title>Open Label Iloperidone</title>
          <description>open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
iloperidone: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores</title>
        <description>The Bipolar Inventory of Symptoms Scale is a reliable and valid measure which assesses Depression and Mania symptoms of bipolar disorder. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period.
For Depression: Items 1-21 items of the assessment are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the depression.
For Mania: Items 22-42 are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the mania. The mean is calculated from the change in score between baseline and week 20.</description>
        <time_frame>Baseline and 20 weeks</time_frame>
        <population>Subjects who are currently treated with mood stabilizers (Lithium, Divalproex or Lamotrigine), with a diagnosis of Bipolar Disorder I or II.</population>
        <group_list>
          <group group_id="O1">
            <title>Mean Change in Depression for Study Completers</title>
            <description>Measurement of mean change in depression for all subjects who entered study and completed 20 weeks</description>
          </group>
          <group group_id="O2">
            <title>Mean Change in Mania for Study Completers</title>
            <description>Measurement of mean change in mania for all study participants who completed 20 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Mean Change in Depression for All Study Participants</title>
            <description>Mean change in depression for all study participants, including early terminators.</description>
          </group>
          <group group_id="O4">
            <title>Mean Change in Mania for All Study Participants</title>
            <description>Mean change in mania for all study participants, including early terminators</description>
          </group>
        </group_list>
        <measure>
          <title>Measure of Response by Change From Baseline to End of Study in BISS Depression and Mania Scale Scores</title>
          <description>The Bipolar Inventory of Symptoms Scale is a reliable and valid measure which assesses Depression and Mania symptoms of bipolar disorder. There are 42 items; each item is rated on a 0-4 scale. The BISS is a clinician-rated instrument. The Scale is rated as follows:
0 Not at all
Slight
Mild
Moderate
Severe Each of the 42 items is rated separately, with a score, based on the most recent 7 day period.
For Depression: Items 1-21 items of the assessment are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the depression.
For Mania: Items 22-42 are summed up and multiplied by 4 to give a cumulative score out of 84. The higher the score, the more severe the mania. The mean is calculated from the change in score between baseline and week 20.</description>
          <population>Subjects who are currently treated with mood stabilizers (Lithium, Divalproex or Lamotrigine), with a diagnosis of Bipolar Disorder I or II.</population>
          <units>percentage change in score on BISS scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="61.8"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>BISS Outcomes: Mean changes in depression and mania for study completers were measured. The a priori hypothesis was a mean change of 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0094</p_value>
            <p_value_desc>p value is not adjusted for multiple comparisons (see above). A priori threshold for significance was p&lt;0.05.</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-14.9</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>20.0</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>BISS Outcomes: Mean changes in mania for study completers were measured. The a priori hypothesis was a mean change of 50%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>10.1</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Iloperidone</title>
          <description>open label iloperidone (oral tablet, 6mg-24mg, QD, 20 weeks) as adjunct to current lithium, divalproex, or lamotrigine.
iloperidone: Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Edema of the legs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart palpitations</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Atrial fibrilation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Thirst</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurry vision</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dry Eyes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dry mouth</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhea/Loose stool</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Abdominal Bloating</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Flu symptoms/muscle weakness/fatigue</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>weight gain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>worsening of Fibromyalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizzy/lightheaded</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Migraine headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Decreased concertration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension(high blood pressure)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Charles Bowden, MD</name_or_title>
      <organization>University of Texas HEalth Science Center San Antonio</organization>
      <phone>210-567-5405</phone>
      <email>BowdenC@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

